Big Pharma Accused of Free-Riding on Nature as Cali Fund Stalls 2026

Big pharmaceutical companies are being accused of “free-riding on nature” after a global biodiversity fund designed to capture a share of their profits attracted a mere $10,656 in commitments. The Cali Fund, launched over 18 months ago, aims to raise $1 billion annually from companies that benefit from nature’s genetic resources. So far, it has received just $7,085 in actual deposits, with no contributions from major drugmakers.

The fund was established to support conservation efforts in low-income countries, which often provide the genetic diversity that fuels pharmaceutical research. Despite the industry’s reliance on these resources, not a single major pharmaceutical company has stepped forward.

What Is the Cali Fund and Why Does It Matter?

The Cali Fund was created as part of the global biodiversity framework to ensure that companies profiting from genetic information—such as the DNA of plants, animals, and microbes—contribute back to conservation. It asks businesses to voluntarily contribute 1% of their profits or 0.1% of their revenue.

The fund’s goal is to channel $1 billion per year into protecting ecosystems, particularly in developing nations that are rich in biodiversity but lack the resources to safeguard it. However, the fund’s near-empty coffers raise serious questions about corporate responsibility and the effectiveness of voluntary mechanisms.

Pharma’s Profits vs. Contributions

A study by Zero Carbon Analytics (ZCA) found that the top 15 pharmaceutical companies could have contributed $756 million based on their 2025 performance, if they had followed the fund’s guidelines. In 2025 alone, these companies generated approximately $161 billion in profits.

“Look at how much profit these pharmaceutical companies are getting – and we’re only asking for a tiny fraction,” said a representative from ZCA. The disparity highlights the gap between voluntary commitments and actual action.

The Impact on Biodiversity Conservation

Without meaningful contributions from the pharmaceutical industry, the Cali Fund will struggle to meet its ambitious target. This shortfall could undermine global conservation efforts, especially in regions where biodiversity is most threatened.

Low-income countries often lack the financial means to protect their natural habitats, making international funding critical. The Cali Fund was designed to be a fair and equitable solution, but its success depends on industry participation.

Key Takeaways

• The Cali Fund has raised only $10,656 in commitments, far short of its $1 billion annual goal.
• No major pharmaceutical company has contributed, despite relying on genetic resources for drug development.
• Top 15 pharma companies could have contributed $756 million based on 2025 profits.
• The fund aims to support conservation in low-income countries, but voluntary contributions are not materializing.
• Critics accuse big pharma of “free-riding on nature” and call for mandatory contributions.

Comparison of Potential vs. Actual Contributions

What’s Next for the Cali Fund?

As the Cop17 biodiversity summit begins in Armenia, pressure is mounting on governments and corporations to address the funding gap. The summit will likely see renewed calls for mandatory contributions or other mechanisms to ensure fair sharing of benefits from genetic resources. The background to this story is set out in Business: latest articles. A related thread runs through China's 3nm Chip Breakthrough Without EUV Lithography.

The pharmaceutical industry’s participation could prove pivotal. Without it, the Cali Fund may fail to achieve its mission, leaving biodiversity conservation in low-income countries severely underfunded. Earlier coverage in Best Tech Deals on Amazon Today: Kindle Scribe and Samsung OLED shows how the argument developed. A closer look at the same subject appears in Google, Apple, Microsoft Agree: The PC Is Back for AI Agents.

For businesses, the reputational risk of being seen as “free-riding on nature” is significant. As consumers and investors increasingly prioritize sustainability, companies that ignore these calls may face backlash. Anyone following the wider picture can start with LG OLED C6 TV Deal: Save Big on This Year's Model. The same theme surfaces in Nintendo Switch Bundle With Mario Kart 8 Deluxe Launches at $199, which takes a different angle.